Ovarian cancer stem cells: What progress have we made?. (February 2019)

• Record Type: Journal Article
• Authors: Al-Alem, Linah F.; Pandya, Unnati M.; Baker, Andrew T.; Bellio, Chiara; Zarrella, Bianca D.; Clark, Justin; DiGloria, Celeste M.; Rueda, Bo R.
• Is Part Of: International journal of biochemistry & cell biology. Volume 107(2019)
• Page Start: 92
• Page End: 103
• Publication Date: 2019-02
• Subjects: Akt Protein kinase B -- ALDH aldehyde dehydrogenase -- ALDEFLUOR aldehyde dehydrogenase detection reagent -- ATP adenosine triphosphate -- Cadherin calcium dependent adhesion (for E-cadherin) -- CD cluster of differentiation -- CSC cancer stem cell -- CXCR4 C-X-C motif chemokine receptor 4 -- CXCL12 C-X-C motif chemokine ligand 12 -- DNA deoxyribonucleic acid -- Dsh dishevelled -- EMT epithelial-mesenchymal transition -- EZH2 enhancer of zeste homologue 2 -- FDA food and drug administration -- Fz frizzled -- GLI1 GLI family zinc finger 1 -- GLI2 GLI family zinc finger 2 -- H3K27me3 trimethlylation of lysine residue 27 on the amino (N) terminal tail of histone H3 -- H3K4me3 trimethlylation of lysine residue 4 on the amino (N) terminal tail of histone H3 -- IκB inhibitor of kappa B (1 and in IKKa) -- IKKα IκB Kinase alpha -- IPI-926 drug name -- JAK Janus kinase -- MAPK mitogen activated protein kinase -- MDR1 multidrug resistance 1 -- MEK mitogen activated protein kinase kinase -- miR microRNA -- mTOR mammalian target of rapamycin -- MyD88 myeloid differentiation primary response gene 88 -- NANOG nanog homeobox -- NCT National clinical trial -- NFκB nuclear factor kappa light chain enhancer of activated B cells -- NICD1 Notch1 intra-cellular domain -- NSC Normal Stem Cell -- OCT4 octamere binding transcription factor 4 -- OS overall survival -- OvCa ovarian cancer -- PARP poly (ADP-ribose) polymerase -- PDX patient derived xenograft -- PFS progression free survival -- PI3K phosphatidylinositol-4, 5-bisphosphate 3-kinase -- PKC protein kinase C -- PRC2 polycomb repressive complex 2 -- PTEN phosphatase and tensin homolog deleted on chromosome TEN -- ROR1 receptor tyrosine kinase like orphan receptor 1 -- SC stem cell -- SMO smoothened -- SOX2 sex determining region Y (SRY)-box 2 -- SP side population -- ST6GalNAc1 alpha2, 6-sialyltransferase gene -- STAT3 signal transducer and activator of transcription 3 -- STn Sialyl-Tn -- TCGA the cancer genome atlas -- TEAD TEA domain family member -- TGF-β transforming growth factor beta -- TLR toll like receptor -- TNFα tumor necrosis factor alpha -- TP53 gene that transcribes p53 -- Wnt wingless/integrated signaling pathway -- YAP Yes-associated protein -- ZEB1 zinc finger E-box binding homeobox 1; Cancer stem cell -- Ovarian cancer -- Stem cell markers -- Drug resistance -- Pathways -- Clinical trials; Biochemistry -- Periodicals; Cytology -- Periodicals; Biochemistry -- Periodicals; Cell Biology -- Periodicals; Biochimie -- Périodiques; Cytologie -- Périodiques; Biochimie; Cytologie; Biochemistry; Cytology; Ressource Internet (Descripteur de forme); Périodique électronique (Descripteur de forme); Periodicals; 572.05
• DOI: 10.1016/j.biocel.2018.12.010
• Languages: English
• ISSNs: 1357-2725

Abstract

Abstract: Ovarian cancer (OvCa) is the most lethal gynecological malignancy in the United States primarily due to lack of a reliable early diagnostic, high incidence of chemo-resistant recurrent disease as well as profuse tumor heterogeneity. Cancer stem cells (CSCs) continue to gain attention, as they are known to resist chemotherapy, self-renew and re-populate the bulk tumor with undifferentiated and differentiated cells. Moreover, CSCs appear to readily adapt to environmental, immunologic and pharmacologic cues. The plasticity and ability to inactivate or activate signaling pathways promoting their longevity has been, and continues to be, the challenge faced in developing successful CSC targeted therapies. Identifying and understanding unique ovarian CSC markers and the pathways they utilize could reveal new therapeutic opportunities that may offer alternative adjuvant treatment options. Herein, we will discuss the current state of ovarian CSC characterization, their contribution to disease resistance, recurrence and shed light on clinical trials that may target the CSC population.